EPD0793_2_G01 EPD0793_2_D01 EUCOMM-projects EPD0793_2_G04 EPD0793_2_A02 EPD0793_2_E01 EPD0793_2_E03 EPD0562_3_G01 EPD0793_2_C01 EPD0793_2_B03 EPD0793_2_H02 EPD0793_2_H04 EPD0793_2_F02 EPD0793_2_C02 EPD0793_2_C04 EPD0793_2_D02 EPD0562_3_B04 EPD0793_2_F03 EPD0562_3_H02 EPD0562_3_A02 EPD0793_2_A04 EPD0562_3_D01 EPD0562_3_D04 EPD0562_3_D03 EPD0793_2_B04 EPD0562_3_G02 EPD0562_3_F02 EPD0562_3_F01 EPD0793_2_C03 EPD0562_3_F04 EPD0793_2_F04 Ccr10<tm1e(EUCOMM)Wtsi> http://identifiers.org/mgd/MGI:4456762 targeted mutation 1e, Wellcome Trust Sanger Institute EPD0562_3_H01 EPD0793_2_A01 EPD0562_3_A04 MGI:4456762 EPD0793_2_H01 EPD0793_2_H03 EPD0793_2_F01 EPD0562_3_F03